The researchers observed 331 patients who received small doses of the study drug or a placebo. No treatment-related serious adverse effects were reported in either diclofenac dose group, whereas only one was reported in the kerorolac group.
For patients with acute moderate and severe pain after abdominal or pelvic surgery, repeated lower doses of solubilized diclofenac provided significant analgesic efficacy, as compared with the placebo. It significantly reduced the need for opioids.
More Articles on Anesthesia:
Can ASCs Still Profit From Anesthesia? A Review of OIG Guidance
Anesthesiologist Dr. Brian Waltmann Joins MedNet as Medical Director
Regional Anesthesia May Reduce Blood Transfusions for Bilateral Knee Replacements
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
